Community Health Media

Can we improve outcomes by changing treatment before radiographic progression occurs? In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations. Topics discussed include:The clini...

HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease? In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatme...

The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly. Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice. The conversation explores:• The evolution of metastatic TNBC treatment• Why many patients never reach sec...

The treatment landscape for perioperative gastric cancer is changing rapidly. In this expert roundtable, leading GI oncology specialists discuss the practice-changing impact of the MATTERHORN trial, the role of immunotherapy in resectable gastric cancer, and how emerging data from ASCO 2026 is influencing treatment decisions in both academic and community settings. Featuring insights from Dr. Zev...

Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma? In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study. The panel explores the scientific rationale...

How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer? In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors. The conversation examines how m...

How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer? Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-m...

Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer? In this comprehensive discussion from ASCO 2026, Dr. Jason Mouabbi, Dr. Fengting Yan, and Dr. Paolo Tarantino break down the practice-changing DESTINY-Breast09 data and what it means for treatment sequencing, patient selection and toxicity management. Beyond th...

How is T-DXd reshaping treatment for patients with early-stage HER2-positive breast cancer? Dr. Abi Siva and Dr. Carey Anders discuss the evolving role of T-DXd across the treatment continuum, including the latest data from DESTINY-Breast11 and DESTINY-Breast05. The conversation explores how these studies are influencing neoadjuvant and adjuvant treatment strategies, patient selection, toxicity ma...

Metastatic triple-negative breast cancer has long been one of the most challenging breast cancer subtypes to treat. But with the emergence of ADCs, the treatment landscape is rapidly evolving. In this in-depth discussion from ASCO 2026, Dr. Megan Kruse, Dr. Ryan Rader, and Dr. Praveen Vikas explore the latest advances in first-line treatment for metastatic TNBC, including the recently approved dat...

How should clinicians integrate T-DXd across the entire HER2-positive breast cancer treatment continuum? Dr. Megan Kruse, Dr. William Gradishar, and Dr. Ajaz Khan discuss the evolving role of trastuzumab deruxtecan (T-DXd) in early-stage and metastatic HER2-positive breast cancer. From DESTINY-Breast11 and DESTINY-Breast05 to first-line metastatic DESTINY-Breast09 strategies, the conversation expl...

How should clinicians approach endocrine resistance in ER-positive metastatic breast cancer? Dr. Mark Pegram and Dr. Seth Wander explore the evolving science of endocrine resistance, ESR1 mutations, liquid biopsy testing, and precision oncology in hormone receptor-positive, HER2-negative metastatic breast cancer. Drawing from decades of research and clinical experience, they discuss how resistance...

TNBC has long been one of the most difficult breast cancer subtypes to treat. But with ADCs reshaping the treatment landscape, are we finally entering a new era for metastatic TNBC?In this in-depth discussion, Dr. Jason Mouabbi, Dr. Alison Conlin, and Dr. Reva Basho explore the rapidly evolving first-line treatment landscape for metastatic triple-negative breast cancer, with a particular focus on...

How will DESTINY-Breast11 and DESTINY-Breast05 change the treatment of early-stage HER2-positive breast cancer? Dr. Gregory Vidal, Dr. Pooja Advani, and Dr. Tari King discuss the landmark approvals of trastuzumab deruxtecan (T-DXd) and what they mean for medical oncologists and surgeons treating HER2-positive breast cancer. The conversation explores the impressive pathologic complete response rate...

Three new approvals for trastuzumab deruxtecan (T-DXd) are reshaping the treatment landscape for HER2-positive breast cancer. Dr. Hope Rugo, Dr. Sarah Hurvitz, and Dr. Jennifer Tseng discuss the clinical impact of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is changing treatment decisions across both early-stage and metastatic HER2-positive disease. The conversati...

What is the optimal treatment strategy after progression on a CDK4/6 inhibitor in HR-positive, HER2-negative metastatic breast cancer? Dr. Nusayba Bagegni and Dr. Philip Lammers discuss how they approach treatment sequencing in an increasingly complex landscape that now includes AKT inhibitors, oral SERDs, PROTACs, ADCs, and ctDNA-guided decision making. The conversation explores the role of tumor...

What should replace chemotherapy in the first-line treatment of immunotherapy-ineligible metastatic triple-negative breast cancer(TNBC)?Dr. Sangeetha Reddy and Dr. Ahmed Elkhanany discuss the evolving role of antibody-drug conjugates (ADCs) following the recent approval of datopotamab deruxtecan (Dato-DXd) and the growing evidence supporting ADCs over traditional chemotherapy in metastatic TNBC. T...

The treatment for early-stage HER2-positive breast cancer has entered a new era. Dr. Mabel Mardones and Dr. Joyce O'Shaughnessy discuss how they are implementing trastuzumab deruxtecan (T-DXd) following the landmark DESTINY-Breast11 and DESTINY-Breast05 approvals. From patient selection and ILD monitoring to residual disease management and future treatment sequencing, this conversation explore...

The treatment landscape for early-stage HER2-positive breast cancer is evolving rapidly. In this discussion, Dr. Joyce O'Shaughnessy, Dr. Anthony Lucci, and Dr. Mothaffar Rimawi explore how DESTINY-Breast11 (DB11) and DESTINY-Breast05 (DB05) are influencing treatment decisions in early HER2-positive breast cancer. The conversation examines the growing role of neoadjuvant therapy, pathologic co...

How do we navigate the increasingly complex second-line landscape for HR+/HER2- metastatic breast cancer? Dr. Marcela Mazo Canola, Dr. Akshjot Puri, and Dr. Giancarlo Moscol discuss the art of sequencing therapies post-CDK4/6 progression and the evolving role of MRD and circulating tumor DNA (ctDNA) monitoring across ER+ mBC. They discuss the critical clinical judgment required when targeting the...

A new approach to treating endocrine resistance may be emerging in metastatic HR-positive breast cancer with the SERENA-6 trial. Dr. Caitlin Taylor and Dr. Andrew Davis discuss the SERENA-6 trial and the potential role of camizestrant in patients with ESR1-mutated metastatic breast cancer. The conversation explores how ctDNA monitoring may allow clinicians to detect resistance earlier, intervene b...

The treatment landscape for early-stage HER2-positive breast cancer has shifted. Dr. Komal Jhaveri, Dr. Sarah Tolaney, and Dr. Shanu Modi discuss the landmark FDA approvals of trastuzumab deruxtecan (T-DXd) in the early-stage setting, and break down the practice-changing data from the DESTINY-Breast11 and DESTINY-Breast05 trials. They discuss what these results mean for clinical practice and patie...

As the ADC landscape expands, how is datopotamab deruxtecan redefining the treatment paradigm for both breast and lung cancer? In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Lukas Delasos break down the clinical integration of next-generation ADCs. The discussion differentiates the roles of ADCs such as datopotamab deruxtecan and trastuzumab deruxtecan, examining their impact across...

The second-line landscape for HR+/HER2- metastatic breast cancer is shifting rapidly with the detection of truncal mutations. In this episode of CHM Conversations, Dr. Ruta Rao and Dr. Azadeh Nasrazadani discuss how the detection of PIK3CA, AKT, and PTEN mutations is redefining the role of capivasertib. The clinicians differentiate the clinical application of capivasertib from other targeted agent...

How is Dato-DXd redefining first-line mTNBC? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the TROPION-Breast02 trial results and how this data fits into the broader landscape alongside the ASCENT-03 findings. The clinicians focus on the shift toward frontline Trop2-directed strategies and how these agents are challenging the chemotherapy-only paradigm. They a...